U.S. Gas Utilities Stock News

NYSE:KVYO
NYSE:KVYOSoftware

Klaviyo Claude Integration Shifts AI To Execution As Shares Screen Undervalued

Klaviyo (NYSE:KVYO) has launched a deeper integration with Anthropic's Claude through a new Model Context Protocol connector. The update allows marketers to use natural language inside Claude to pull Klaviyo first party data, generate campaigns, and automate multi step workflows. This moves Klaviyo's AI tools from insight generation into direct execution across reporting and campaign creation. Klaviyo is rolling out this Claude integration at a time when the stock is trading at $14.24 and...
NYSE:AON
NYSE:AONInsurance

Has Aon (AON) Share Weakness Opened A Valuation Opportunity For Investors

Wondering whether Aon’s current share price still reflects good value, or if most of the opportunity has already been priced in? This article looks at the stock through a clear valuation lens so you can frame your own view. Aon’s share price closed at US$310.90, with returns of 0.9% over the past week, a decline of 4.5% over the past month, a decline of 9.7% year to date and a decline of 10.9% over the past year. These figures may change how investors think about its risk and return trade...
NYSE:CCL
NYSE:CCLHospitality

Carnival (CCL) Is Down 9.0% After FTSE Exit And Dividend Move - What's Changed

Carnival Corporation Ltd. recently declared a quarterly dividend of US$0.15 per share, payable on May 29, 2026 to shareholders of record on May 18, 2026, while also withdrawing several shelf registrations and seeing its London-listed shares removed from multiple FTSE indices. At the same time, its Cunard brand outlined an extensive 2028 voyage program featuring the first-ever Four Queens Celebration and new Signature Packages, underscoring ongoing investment in premium guest experiences...
NasdaqGS:TRIP
NasdaqGS:TRIPInteractive Media and Services

Tripadvisor (TRIP) Is Down 13.9% After Widening Q1 2026 Losses Despite Stable Revenue – Has The Bull Case Changed?

Tripadvisor, Inc. has already reported first quarter 2026 results, with sales easing to US$382.4 million from US$398.2 million a year earlier and net loss widening to US$32.4 million. The sharper loss per share from continuing operations, rising to US$0.28 from US$0.08, highlights growing pressure on Tripadvisor’s profitability despite relatively stable revenue. With this backdrop of widening quarterly losses, we’ll examine how these results may reshape Tripadvisor’s investment narrative...
NYSE:NIO
NYSE:NIOAuto

NIO (NIO) Valuation Check After Record Deliveries And First Quarterly Net Profit

NIO (NIO) just posted fresh delivery figures that keep attention on the stock. April deliveries reached 29,356 vehicles, with year to date deliveries at 112,821, both showing double digit year over year growth. See our latest analysis for NIO. The strong April delivery update comes as NIO's share price has gained momentum, with a 7.57% 1 day share price return and a 10.85% 7 day share price return. This has contributed to a 27.24% year to date share price return and a 58.35% 1 year total...
NYSE:GVA
NYSE:GVAConstruction

Will Raised 2026 Guidance and New Federal Work Shift Granite Construction's (GVA) Infrastructure Narrative?

In the past quarter, Granite Construction Incorporated reported first-quarter 2026 sales of US$912.47 million, a net loss of US$41.70 million, raised its full‑year 2026 revenue guidance to US$5.2 billion–US$5.4 billion, and was awarded a federally funded US$15 million Glenn Highway pavement preservation contract in Alaska. The combination of stronger reported revenue, higher full‑year guidance, a record contract pipeline, and new federally backed infrastructure work underscores how Granite’s...
NasdaqGS:HUMA
NasdaqGS:HUMABiotechs

Does Humacyte’s (HUMA) Nasdaq Notice Quietly Reframe Its Financing Flexibility And Clinical Adoption Story?

In the first quarter of 2026, Humacyte, Inc. reported revenue of US$495,000, sales of US$2,000, and a net loss of US$17.62 million, alongside a Nasdaq notice that its share price had stayed below the US$1.00 minimum listing requirement. The sharp swing from a US$39.14 million net profit a year earlier to a loss, combined with the compliance warning, raises questions about Humacyte’s operating trajectory and financing flexibility even as it appoints a new Chief Surgical Officer to support...